Get the Stockscreener App
12.67
1.17%
-0.1195
Tourmaline Bio Inc stock is traded at $12.67, with a volume of 33,271.
It is down -1.17% in the last 24 hours and down -23.39% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$12.79
Open:
$12.7
24h Volume:
33,271
Relative Volume:
0.14
Market Cap:
$327.97M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
21.90
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+3.52%
1M Performance:
-23.39%
6M Performance:
-28.18%
1Y Performance:
-67.17%
1-Day Range:
$12.41
$13.01
1-Week Range:
$11.87
$13.41
52-Week Range:
$11.87
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
12.66 | 327.97M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.24 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
695.97 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.76 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.50 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.06 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - Nasdaq
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
We Tested Over 25 Curling Irons. These 13 Are the Best - Marie Claire
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of “Buy” by Analysts - Defense World
ClearOne (NASDAQ:CLRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
StockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to Buy - Defense World
Broadway Financial (NASDAQ:BYFC) Now Covered by StockNews.com - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 16.3% in January - MarketBeat
TrueBlue (TBI) Expected to Announce Earnings on Wednesday - Armenian Reporter
Andersons (ANDE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2024 Earnings - MarketBeat
Leerink Partnrs Weighs in on Tourmaline Bio FY2029 Earnings - MarketBeat
Bleakley Financial Group LLC Purchases 110 Shares of Choice Hotels International, Inc. (NYSE:CHH) - Defense World
In the crowded cardio space, it’s David vs. Goliath for small biotechs - PharmaVoice
Jennison Associates LLC Trims Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio Inc (TRML) Stock Showcases -13.66% 20-Day Moving Average - The News Heater
TRML’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Solventum Corp (SOLV) Shares Down Despite Recent Market Volatility - The News Heater
Tourmaline Bio Inc (TRML) Becoming More Attractive for Investors - Knox Daily
In the Green: JBDI Holdings Ltd (JBDI) Closes at 0.65, Up/Down 11.02 from Previous Day - The Dwinnex
Closing Bell Recap: E.W. Scripps Co (SSP) Ends at 1.88, Reflecting a 6.82 Upturn - The Dwinnex
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Daily Market Movement: Tourmaline Bio Inc (TRML) Sees a 6.37 Increase, Closing at 16.53 - The Dwinnex
Keeping an Eye on Entegris Inc (ENTG) After Insider Trading Activity - Knox Daily
Potential Price Increase for Monster Beverage Corp (MNST) After Recent Insider Activity - Knox Daily
Recent Insider Activity Suggests Potential Gains for Vita Coco Company Inc (COCO) - Knox Daily
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8% - MarketBeat
JPMorgan Chase & Co. Acquires 2,100 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
Graves Ophthalmopathy Market to Expand Significantly by 2034, - openPR
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference - Marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Graves' Disease Market Size in the 7MM was ~USD 4,400 million - openPR
Cantor Fitzgerald Estimates Tourmaline Bio FY2025 Earnings - Defense World
Brokers Issue Forecasts for Tourmaline Bio FY2025 Earnings - MarketBeat
Barclays PLC Purchases Shares of 73,897 Mitsubishi UFJ Financial Group, Inc. (NYSE:MUFG) - Defense World
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tourmaline Bio Inc Stock (TRML) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
1.44%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):